Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2019

View Archived Issues

Improbability research yields path to HIV vaccine

Manageable safety and activity seen with GDC-0077 combination treatments in phase Ib study

Phase I data presented for the novel M1 mAChR modulator VU-319

TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD

EGFL7 as a new therapeutic target in AML

Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL

Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923

Prescient presents promising interim phase Ib data for PTX-200 in ovarian cancer

Soligenix initiates phase Ic study of RiVax

Kaleido to advance KB-174 for HE based on topline data from study in patients with cirrhosis

First phase III data for YF-H-2015005 shows rapid mobilization of CD34+ cells

New long-acting HIV-1 fusion inhibitor-based regimen developed

DPP8 may be a target for multiple myeloma therapy by inducing apoptotic cell death

Antabio SAS patents new antibacterial compounds

Adlai Nortye divulges new CSF1R inhibitors

Innovent Biologics presents PI3K inhibitors

DYRK2 is a critical checkpoint in the control of leukemia stem cell maintenance

Merck & Co. describes new IDO1 inhibitors

Study confirms target engagement with BTRX-335140 in healthy volunteers

C&C Research Laboratories identifies STAT3 inhibitors

OrphoMed begins phase II study of ORP-101 in IBS-D

New phase II trial investigates CFZ-533 in pediatric and young adults with type 1 diabetes

Phase III study of Tecentriq with Cotellic and Zelboraf in melanoma meets primary endpoint

Phase II study of TG-4010 combination regimen in advanced NSCLC fails to meet primary endpoint

FDA grants accelerated approval to Vyondys 53 for DMD in patients amenable to skipping exon 53

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...